all report title image
  • Published On : Jun 2022
  • Code : CMI5043
  • Industry : Biotechnology
  • Pages : 156
  • Formats :

Wound care biologics refer to drugs extracted or semi-synthesized from natural sources which are used for controlling and healing infections. Wound care biologics are one of the widely preferred treatments in case of burns, as they enable fast recovery with minimum or no complications. Wound care biologics are mainly used for the management of diabetic, venous, arterial, and pressure ulcers.

The Asia Pacific wound care biologics market is estimated to be valued at US$ 296.1 Mn in 2022 and expected to exhibit a CAGR of 7.6% during the forecast period (2022-2030).

Figure 1. Asia Pacific Wound Care Biologics Market Share (%) in Terms of Value, By Product Type, 2022

Asia Pacific Wound Care Biologics  | Coherent Market Insights

The increasing prevalence of diabetes is expected to drive the market growth during the forecast period.

The increasing prevalence of diabetes in Asia is expected to drive the Asia Pacific wound care biologics market growth over the forecast period. For instance, according to the data published in Journal of Diabetology in 2018, the number of people with diabetes in Southeast Asia in 2017 was 80 million, and this is expected to increase to 151 million by 2045.

CMI table icon

Asia Pacific Wound Care Biologics Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 296.1 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 7.6% 2030 Value Projection: US$ 533.8 Mn
Geographies covered:
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of APAC
Segments covered:
  • By Product Type: Biologic Skin Substitutes, Enzyme Based Formulations, Growth Factors
  • By Application: Chronic Wounds (Diabetic Foot Ulcers, Venous Leg Ulcers, Pressure Ulcers), Acute Wounds (Surgical Wounds, Burns)
  • By End User: Hospitals (In-patient Settings, Out-patient Settings), Clinics, Ambulatory Surgical Centers, Home Care Settings
Companies covered:

Smith & Nephew Plc, Organogenesis, Inc., Integra LifeSciences Holdings Corporation, Skye Biologics, Alphatec Holdings, Inc., Solsys Medical LLC, Amnio Technology LLC, Osiris Therapeutics, Inc., Anika Therapeutics, Inc., Zimmer Biomet, Wright Medical Group N.V., and Kerecis.

Growth Drivers:
  • Increasing prevalence of diabetes
  • Rising incidence of chronic wounds and ulcers
  • A rise in medical tourism favoring the demand for wound care biologic products Robust product pipeline
Restraints & Challenges:
  • Increasing adoption of alternative wound care products 

Figure 2. Asia Pacific Wound Care Biologics Market Share (%), By Application, 2022

Asia Pacific Wound Care Biologics  | Coherent Market Insights

The rising incidence of chronic wounds and ulcers is expected to drive the market growth during the forecast period.

The rising incidence of chronic wounds and ulcers is expected to propel the Asia Pacific wound care biologics market growth over forecast period. For instance, according to data published by the World Health Organization (WHO) in March 2018, over 1,000,000 people were moderately or severely burnt every year in India

Asia Pacific Wound Care Biologics Market – Impact of Coronavirus (COVID-19) Pandemic

Supply chain and manufacturing activities in India and China have been disrupted due to lockdowns implemented by governments for the past two years. The coronavirus or COVID-19 outbreak that started from Wuhan, China has spread across continents, affecting various industries globally. The supply of key materials has been severely disrupted due to forced quarantine and lack of labor and raw materials. As the link between regional warehouses is not smooth, the transportation of raw materials between regions cannot be carried out successfully. This shortage of raw materials and components has affected the supply chain of the Asia Pacific wound care biologics market. Due to a severe shortage of medical resources at the front line, only patients diagnosed with serious conditions can be hospitalized. Unfortunately, the pathogenic mechanism of the virus has not been identified completely, and therefore, there is no specific drug and treatment except for symptomatic and supportive treatments. Respiratory support devices such as life-support machines, atomizer, oxygen generators, and monitors are primary clinical treatment medical devices for the COVID-19. Thus, from diagnosis to cure, the need for instruments for measuring temperature, nucleic acid diagnostic kits, antiviral medical products, and life-support machines have increased consistently. Furthermore, the COVID-19 pandemic has impacted the global economy, and in turn, the Asia Pacific wound care biologics market. Quarantines, traveling constraints, and social distancing measures are likely to lead to a steep decline in business and consumer spending.

Asia Pacific Wound Care Biologics Market: Restraint

The major factors that may hinder the Asia Pacific wound care biologics market growth include the increasing adoption of alternative wound care products. Wound care biologic products are relatively expensive, significantly contributing towards the cost of total wound management procedure, thereby deterring the patients from seeking advanced wound care. This is a major factor responsible for the increasing inclination of patients towards traditional wound care management techniques such as traditional and antimicrobial dressing.

Key Players

Major players operating in the Asia Pacific wound care biologics market include Smith & Nephew Plc, Organogenesis, Inc., Integra LifeSciences Holdings Corporation, Skye Biologics, Alphatec Holdings, Inc., Solsys Medical LLC, Amnio Technology LLC, Osiris Therapeutics, Inc., Anika Therapeutics, Inc., Zimmer Biomet, Wright Medical Group N.V., and Kerecis.

Wound care biologics are bioengineered products used for non-healing wounds of the lower extremity. Wound care biologic dressings are increasingly used in post surgeries and severe trauma cases, as they provide a moist healing environment aiding heat, protein, and electrolyte loss for faster healing and prevent bacterial contamination. Biologic skin substitutes are healing therapies intended to facilitate innate repair mechanisms, control associated pain, and promote healing of the wound. Enzyme-based formulations including collagen play an essential role in wound healing such as hemostasis, inflammation, and remodeling, as collagen facilitates wound healing through the organization and accumulation of freshly formed fibers and granulation tissue, creating a healing environment. Growth factors are polypeptides that control the growth, differentiation, and metabolism of cells. These factors are hormone-like molecules that interact with specific cell surface receptors to control the process of tissue repair.

Market Dynamics

Rising medical tourism in Asia Pacific is encouraging an influx of foreign patients for affordable treatment. This had been facilitating hospitals, wound care clinics, and ambulatory surgical care centers to expand the range of wound care biologics products that are used post-surgical interventions for wound management. For instance, according to data published by Health Analytics Asia, a data-driven platform to bring journalists, doctors, and data scientists together to shape health reporting in Asia, in 2019, it had been reported that one million medical tourists visited Malaysia and 3.3 million medical tourists visited Thailand in 2017. India also saw a surge from 4,27,014 medical tourists in 2016 to 4,95,056 medical tourists in 2017.

Key features of the study:

  • This report provides an in-depth analysis of the Asia Pacific wound care biologics market, market size (US$ Mn), and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the Asia Pacific Wound Care Biologics Market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Smith & Nephew Plc, Organogenesis, Inc., Integra LifeSciences Holdings Corporation, Skye Biologics, Alphatec Holdings, Inc., Solsys Medical LLC, Amnio Technology LLC, Osiris Therapeutics, Inc., Anika Therapeutics, Inc., Zimmer Biomet, Wright Medical Group N.V., and Kerecis
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The Asia Pacific Wound Care Biologics Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Asia Pacific wound care biologics market

Detailed Segmentation:

  • Asia Pacific Wound Care Biologics Market, By Product Type:
    • Biologic Skin Substitutes
    • Enzyme Based Formulations
    • Growth Factors
  • Asia Pacific Wound Care Biologics Market, By Application:
    • Chronic Wounds
      • Diabetic Foot Ulcers
      • Venous Leg Ulcers
      • Pressure Ulcers
    • Acute Wounds
      • Surgical Wounds
      • Burns
  • Asia Pacific Wound Care Biologics Market, By End User:
    • Hospitals
      • In-patient Settings
      • Out-patient Settings
    • Clinics
    • Ambulatory Surgical Centers
    • Home Care Settings
  • Asia Pacific Wound Care Biologics Market, By Country:
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of APAC
  • Company Profiles
    • Smith & Nephew Plc *
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Organogenesis, Inc.
    • Integra LifeSciences Holdings Corporation
    • Skye Biologics
    • Alphatec Holdings, Inc.
    • Solsys Medical LLC
    • Amnio Technology LLC
    • Osiris Therapeutics, Inc.
    • Anika Therapeutics, Inc.
    • Zimmer Biomet
    • Wright Medical Group N.V.
    • Kerecis

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The Asia Pacific wound care biologics market is estimated to be valued at US$ 296.1 Mn in 2022 and expected to exhibit a CAGR of 7.6% between 2022 and 2030.
The increasing prevalence of diabetes, rising incidence of chronic wounds and ulcers, and rising medical tourism are favoring the demand for wound care biologic products, which is expected to drive the market growth during the forecast period.
The biologic skin substitutes segment is expected to hold a major market share in the market over the forecast period.
The major factors hampering the market growth include the increasing adoption of alternative wound care products.
Major players operating in the market include Smith & Nephew Plc, Organogenesis, Inc., Integra LifeSciences Holdings Corporation, Skye Biologics, Alphatec Holdings, Inc., Solsys Medical LLC, Amnio Technology LLC, Osiris Therapeutics, Inc., Anika Therapeutics, Inc., Zimmer Biomet, Wright Medical Group N.V., and Kerecis.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo